HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- methoxycarbonylamino- N- acetyltryptamine

an mt1/MT2 receptor agonist

Also Known As:

5-MCA-NAT

Networked: 8 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Biogenic Amines: 992
    - Biogenic Monoamines: 29
      - Tryptamines: 1679
        5-methoxycarbonylamino-N-acetyltryptamine: 8
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Tryptamines: 1679
        5-methoxycarbonylamino-N-acetyltryptamine: 8

Experts

1.	Pintor, Jesús: 6 articles (10/2019 - 12/2007)
2.	Crooke, Almudena: 3 articles (10/2019 - 12/2007)
3.	Peral, Assumpta: 3 articles (03/2011 - 12/2007)
4.	Huete-Toral, Fernando: 2 articles (10/2019 - 07/2013)
5.	Martínez-Águila, Alejandro: 2 articles (05/2016 - 07/2013)
6.	Andrés-Guerrero, Vanessa: 2 articles (03/2011 - 03/2009)
7.	Herrero-Vanrell, Rocío: 2 articles (03/2011 - 03/2009)
8.	Molina-Martínez, Irene T: 2 articles (03/2011 - 03/2009)
9.	Alarma-Estrany, Pilar: 2 articles (03/2009 - 12/2007)
10.	Carracedo, Gonzalo: 1 article (10/2019)

Related Diseases

1.	Reperfusion Injury 01/01/2000 - "In conclusion, both melatonin and its structural analog, 5-MCA-NAT, appear to confer protection against ischemia-reperfusion injury in the isolated rat heart. " 01/01/2000 - "Results show a spectacular protection against ischemia-reperfusion injuries (on arrhythmias as well as on infarct size) in rats pre-treated with 10 mg/kg of melatonin or 5-MCA-NAT. "
2.	Infarction (Infarctions) 01/01/2000 - "Results show a spectacular protection against ischemia-reperfusion injuries (on arrhythmias as well as on infarct size) in rats pre-treated with 10 mg/kg of melatonin or 5-MCA-NAT. "
3.	Glaucoma 05/01/2016 - "In addition, 5-MCA-NAT was tested to determine its effects on ameliorating increased IOP in a glaucoma model. " 10/01/2004 - "This study evaluates the effect of topical application of 5-MCA-NAT on IOP in monkey eyes with laser-induced unilateral glaucoma. " 03/01/2009 - "Therefore, the use of 5-MCA-NAT may be possible in the treatment of ocular hypertension and glaucoma." 05/01/2016 - "In conclusion, melatonin and 5-MCA-NAT can effectively reduce IOP in a glaucoma model, and their hypotensive effects are more profound in the glaucoma model than in control animals. " 03/18/2011 - "The use of 5-MCA-NAT combined with bioadhesive polymers is a good strategy in the treatment of ocular hypertension and glaucoma."
4.	Ocular Hypertension (Glaucoma, Suspect) 03/01/2009 - "Therefore, the use of 5-MCA-NAT may be possible in the treatment of ocular hypertension and glaucoma." 03/18/2011 - "The use of 5-MCA-NAT combined with bioadhesive polymers is a good strategy in the treatment of ocular hypertension and glaucoma." 12/30/2007 - "Melatonin and its analogue, 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT), potently reduce intraocular pressure, and may be good candidates for the treatment of ocular hypertension and glaucoma. "
5.	Dry Eye Syndromes (Dry Eye Syndrome) 10/01/2019 - "Therefore, agomelatine, IIK7, and 5-MCA-NAT act through MT membrane receptors as secretagogues of tear secretion, and these analogs could be considered excellent therapeutic candidates for dry eye treatment. "

Related Drugs and Biologics

1.	Melatonin
2.	Adrenergic Receptors (Adrenergic Receptor)
3.	Polymers
4.	Secretagogues
5.	IIK7
6.	agomelatine (S20098)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Therapeutics